AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging workAEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026AEON plans to leverage its anal…